Netupitant and palonosetron Approval Status 
- FDA approved: No
- Generic name: netupitant and palonosetron
- Company: Helsinn Group and Eisai Inc.
- Treatment for: Nausea/Vomiting, Chemotherapy Induced
Netupitant and palonosetron is an investigational oral fixed-dose combination of the selective NK1 receptor antagonist netupitant and the 5-HT3 receptor antagonist palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).
FDA Approval Status for netupitant and palonosetron
| Date | Article |
|---|---|
| Jan 12, 2011 | FDA Agrees to Special Protocol Assessment (SPA) to Evaluate the Safety and Efficacy of a Fixed-Dose Combination (FDC) of Netupitant and Palonosetron in the Prevention of CINV |
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
